Journal Of Clinical Oncology (jco) Podcast

In this podcast, Dr. Hudis reviews the use of a novel nomogram to predict the benefits of postoperative adjuvant radiation therapy for older women with early stage breast cancer. This discussion highlights the information from prospective randomized trials, their limitations, and the potential for a nomogram to guide clinicians facing patients who might not have qualified for the earlier studies.

As oncologists treat an increasing number of older patients with colon cancer, and as treatment options improve for older patients, oncologists should work with geriatricians to make the best treatment decisions.

This podcast will provide a critical evaluation of the combination of bortezomib, thalidomide, and dexamethasone in relapsed multiple myeloma

This Podcast reviews and comments on the use of the National Comprehensive Cancer Network (NCCN) Breast Cancer Outcome Database to demonstrate the actual rollout of the use of gene expression profile (GEP) testing for women with hormone receptor positive, node negative breast cancer and the accompanying changes in breast cancer chemotherapy utilization

This Podcast reviews the design and results of the present study by Kennecke et al. and provides perspective regarding the clinical significance of these findings.

This podcast reviews the rationale behind evaluation of metformin as a potential anti-cancer agent in breast cancer and describes the findings of a recent window of opportunity trial looking at the impact of metformin upon proliferative indices in women with early breast cancer.

This podcast reviews the results of the FACT trial in the context of other ongoing and proposed studies of endocrine therapy combinations.

This podcast describes a phase 2 trial brentuximab vedotin in patients with Hodgkin lymphoma that has recurred after autologous hematopoietic stem cell transplantation. The podcast discusses the rationale for the trial, response to therapy, and associated toxicities. Future application of brentuximab vedotin to CD30+ malignancies is considered as well.

In this study, the implications of long term follow up of the German Rectal Study on clinical practice and future trial design will be discussed.

Carboplatin-Gemcitabine-Bevacizumab represents an additional regimen to consider for management of recurrent platinum sensitive epithelial ovarian cancer, although it raises several questions regarding the role of bevacizumab in this disease setting.

This podcast discusses adjuvant therapy in elderly NSCLC patients.

The podcast highlights recent JCO articles that underscore the need for improved assessment and management of cancer and treatment-related symptoms.

The CHER-LOB trial is one of several that has demonstrated that adding lapatinib to trastuzumab and chemotherapy improves on the rates of complete pathological response among women receiving neoadjuvant therapy for HER2 positive breast cancer. Because the relationship between pCR and long-term outcomes remains ambiguous, this regimen is not recommended for ordinary use. However, these findings are a powerful support to the hypothesis that dual-modality anti-HER2 therapy is a potent combination.

A reflection on the problems clinicians face when making a decision on how best to advise patients regarding management of early clear cell carcinoma of the ovary.

This podcast provides observations and commentary on the JCO article "High risk of symptomatic cardiac events in childhood cancer survivors.

This podcast reviews a negative phase III clinical trial of cetuximab combined with chemotherapy in first-line metastatic colorectal cancer and focuses on the interaction of targeted therapy combined with chemotherapy.

This podcast partitions patients with early melanoma into those with very favorable features and compares them to those with a higher risk for dying of metastatic melanoma.

Incorporating the information form Dr Marconi's systematic review on the question "Does sedation at the end of life hasten death", I will provide useful guidance regarding how to discuss this issues with patients and their families.

This podcast describes the results from a subgroup of 732 women in the NSABP B-24 trial for the treatment of DCIS, where ER status was available, and describes how this can be used as a predictive test for response to adjuvant tamoxifen.

In this podcast, I will review a JCO article showing that the publication of CALGB C9343 trial results had little influence in practice patterns in the United States. I will discuss possible study-specific reasons for the lack in change of practice and explore the author’s implication that practitioners are more apt to adopt trials that add technologies and/or treatments compared to those that withhold therapies.